Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions

Nuclear Medicine and Biology

Volumn 30, Issue 3, 2003, Pages 233-240

  Ma, Ying ^a   Kiesewetter, Dale O ^a   Lang, Lixin ^a   Der, Margaret ^a   Huang, Bill ^a   Carson, Richard E ^a   Eckelman, William C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [(3 FLUOROPROPYL)THIO] 1,2,5 THIADIAZOL 4 YL] 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE F 18; FLUOROCYCLOHEXANE CARBOXYLIC ACID F 18; N [2 [4 (2 METHOXYPHENYL)PIPERAZINO]ETHYL] N (2 PYRIDINYL) 4 FLUOROCYCLOHEXANECARBOXAMIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FP TZTP; FP-TZTP; LIGAND; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACCURACY; ARTICLE; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; SOLID PHASE EXTRACTION; THIN LAYER CHROMATOGRAPHY; BLOOD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; METABOLISM;

CHROMATOGRAPHY, THIN LAYER; HUMANS; LIGANDS; PYRIDINES; THIAZOLES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037721267     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00452-3     Document Type: Article

References (13)

1. Carson R.E., Daube-Witherspoon M.E., Herscovitch P. Quantitative Functional Brain Imaging with Positron Emission Tomography. 1998;Academic Press, San Diego.
2. 18F]FP-TZTP control and competition studies . J. Cereb. Blood Flow Metab. 18:1998;1130-1142.
3. 1A receptor antagonist, WAY-100635. Nucl. Med. Biol. 27. 2000;493-497.
4. Halldin C., Swahn C.G., Farde L., Sedvall G. Radioligand disposition and metabolism-Key information in drug development. Comar D. PET for Drug Development and Evaluation. 1995;55-61 Kluwer Academic Publishers, Boston.
5. Kiesewetter D.O., Lee J.T., Lang L., Park S.H., Paik C.H., Eckelman W.C. Preparation of 18F-labeled muscarinic agonist with M2 selectivity. J. Med. Chem. 38:1995;5-8.
6. Kiesewetter D.O., Carson R.E., Jagoda E.M., Herscovitch P., Eckelman W.C. In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines. Synapse. 31:1999;29-40.
7. 18F]FP-TZTP. Nucl. Med. Biol. 30 (2003) 73-77.
8. 1A antagonists. J. Med. Chem. 42:1999;1576-1586.
9. Lang L., Jagoda E., Schmall B., Sassaman M., Ma Y., Eckelman W.C. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. Nucl. Med. Biol. 27:2000;457-462.
10. 1A antagonists, N-{2-[4-(2-methoxylphenyl)piperazino]ethyl}-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes. J. Chromatogr. B. 755:2001;47-56.
11. Ma Y., Kiesewetter D.O., Lang L., Jagoda E., Huang B.X., Eckelman W.C. Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]- 1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes. J. Chromatogr. B. 766:2002;319-329.
12. Stöcklin G., Pike V.W. Radiopharmaceuticals for positron emission tomography - methodological aspects. 1993;Kluwer Academic Publishers, Boston.
13. Wu Y., Lang L., Ma Y., Der M.G., Herscovitch P., Eckelman W.C., Carson R.E. Uptake of radiolabeled acid metabolites into monkey brain. J. Nucl. Med. 43:(5):2002;960.